At current $1.5s.level , could be double in January , total market value is only $36m, and Japanese co want invest $48m on anth , everything tells me that ANTH is way-oversold , so cheap . Buy in year-end , sell in January .
Only 6 more trading days left , so u know they're collect cheap shares from our loser small investor , Market up Anth down , Do u wanna sell your shares know?
simple answer is Lupus medication. If Blisibimod is effective in subjects with systemic Lupus Erythematosus ANTH cap should at least similar to HGSI that was acquired by GSK for $3B. Main goal was HGSI lupus drug that received approval from the Food and Drug Administration, making it the first new treatment for the disease in about 50 years.
Primary Outcome Measure in Phase III CHABLIS-SC1:
Proportion of patients achieving an SLE Responder Index at week 52
I think that ANTH drug has very high probability ( 70%) to meet primary goals. If I'm right we will see double digits pps in 2015.
Sentiment: Strong Buy
any idea of when interim analyses will be announced? has potential to cause price jump from which to sell stock at 30% premium to partner although jump must be sustained for 20 days to have impact. even if sale were to be done now, the dilution would be minimal.
also why do u see potential for double digits next year? what will drive it? TIA
don't worry. ANTH pps will grow in 2015 and may be we will see double digits pps next year.
I'll add more ANTH positions at current pps (may be up to 10% of my portfolio).
Interim analyses of CHABLIS-SC1 and BRIGHT-SC were planned for the third quarter of 2014 to confirm the clinical assumptions of the designs of these two studies. However, due to our on-going partnership negotiations for Asian rights for blisibimod for both lupus and IgA nephropathy, we elected to delay these analyses. We expect these discussions will be completed during the fourth quarter of 2014.
Phase III CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus
Estimated Enrollment: 400
Study Start Date: February 2013
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration
Estimated Enrollment: 200
Study Start Date: July 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2015 (Final data collection date for primary outcome measure)
Sentiment: Strong Buy
Read the 8K. Within 30 days, $7M shares at 30% premium to 20 d MA = $2.52 if exercised today resulting in additional 2.8M shares. Additional $8M shares over next 2 yrs (hopefully higher price) with option for $4M later.
initial marke reaction - wow getting a lot of $. :)
later market reaction - but its in form of stock and debt rather than cash :(
so we have manic depressive reaction. overall its a positive imo
debt at 1% interest due 2021. forgiven if certain milestones are met. in addition to financing, Japanese co will fund part of devel costs. details in 8-K to be filed shortly.
That will get the ball rolling. So far, SA "on the move" hasn't yet picked up the NR. I only saw it cuz i'm email registered with Anthera. MarketWatch has it though.
$48M JV is pretty big news for a stock with just $47M market cap.
Anthera to receive up to $48,000,000 plus future product margin on commercial supply
- Zenyaku to reimburse Anthera for a portion of future blisibimod worldwide development costs
- Zenyaku to assume full responsibility for development and associated costs in Japan and potentially other Asian territories in the future
- Companies will collaborate on blisibimod development for both IgA Nephropathy ("IgAN") and Systemic Lupus Erythematosus ("Lupus")